Archive | September, 2014

Video: Five Family Offices Discuss Life Science Investment at RESI 3

26 Sep

By Dennis Ford, Founder & CEO, LSN

Dennis bookAt LSN’s third Redefining Early Stage Investments (RESI) Conference, leaders from five family offices around the world gathered under the same roof at Fenway Park, answering questions such as: Why do family offices invest directly? How do they assess early stage opportunities? How do you find family offices? How do you build a quality relationship with a family office? Do family offices do deals with third party fundraising partners? How important is branding and messaging?

Click on the video below to hear the views of these five family offices. The video is 70 minutes, and well worth the viewing time.

Moderator:
Bill Brah, Founder & Executive Director, UMass Venture Development Center
Panelists:
Melissa Krauth, Principal, Claria Bioscience
Meredith Fisher, Director & Partner Investments, Private Investment Office
Christopher De Souza, Director, Broadview Ventures
Alejandra Paredones, CEO & Founder, BSI Capital Group
Todd Holmes, Director, Gurnet Point Capital

 

Meeting Follow-Up: Why and How

25 Sep

By Michael Quigley, Director of Research, LSN

mike-2As an entrepreneur in the midst of a fundraising campaign and all that it entails—networking events, conferences, referrals, and cold calls—you are going to meet with a substantial number of people who are either potential investors in your technology or who could connect you with someone who is. Following up with these new contacts after an initial meeting or conversation can make or break your campaign. Here are some key reasons why following up is so crucial and what it can do for your campaign.

It Shows Professionalism

By taking the time to send follow-up messages to recent contacts, you are demonstrating your aptitude and professionalism as an entrepreneur. You are going to be managing potentially hundreds of relationships, and most people you speak to will be aware of that. So taking the time to send a personalized follow-up message in a timely manner shows your level of organization. This ultimately reflects positively on your investment opportunity. With investors viewing management as one of the most crucial pieces of any early stage life science investment, you need to do whatever you can to demonstrate you are on top of things.

It Creates a Dialogue That Fosters a Relationship, Which in Turn Can Elicit an Allocation

The goal of your fundraising campaign is not only to get cash but also to find the right partners to help you grow your business. Therefore, whenever you’re meeting with new investors or other strategic partners, you should keep in mind that you are here to establish a professional relationship. Even investors who are not a fit for your opportunity today may be interested in speaking with you down the road as you hit certain milestones, or they may be able to refer you to other investors they know who might be interested. By maintaining a dialogue with these groups, you can leverage your network to gain more contacts, as well as stay on their radar for when you reach those milestones and are looking to raise an additional round.         

It Can Clarify Any Potential Miscommunication

By following up and mentioning some of the specifics from your conversation, you can bring to light any miscommunication between you and the person that you met. Whether clarifying the next steps in the evaluation process, the information they need to see from your firm, why they can’t invest at present, or who they would like to put you in touch with, by sending that follow-up message you help make sure that nothing falls through the cracks.

Now that we’ve discussed the reasons why follow-up is so important, here are some best practices for how go about following up after an initial meeting.

How you follow-up should depend largely on your current relationship, their level of interest in your opportunity, and where your conversation left off. For investors that have clearly stated a high interest, you want to follow up with haste. Ideally, you should be trying to set up a time for a follow-up call toward the end of the original conversation, if possible. If not, an email including your investor deck and proposing a call should be sent no later than the following day. If they are interested, they will be glad you have shown this initiative and will coordinate a time for further discussion.

If the investor seems interested but not highly compelled to fund your opportunity, it is wise to follow up periodically. By checking in from time to time, you remain on their radar for both referrals and a potential investment as you obtain more supporting data. Also, it is always a great idea to ask if they will be in your area or going to any conferences that you will also be attending so that you may meet in person. Face-to-face meetings are always the most valuable and could turn a mild interest to a more serious interest.

If the investor is not interested due to your level of clinical data, then it is wise to continually follow up with them as you obtain more data, even if is still under the level they are looking for. By keeping them abreast to your companies’ successes, the investor will grow more familiar with your technology, which may make them more likely to allocate down the road.

In cases where the investor is not interested in your opportunity due to the indication you are targeting or the underlying science behind your technology, then following up should be limited to a simple email thanking them for their time. In a best case scenario, they will refer you to someone they know that may be interested, but other than a single email, following up with these investors will only slow you down. This is why you should always try to identify the reasons behind an investor’s lack of interest; this information will help you better understand how to tweak your marketing materials as well as how you should or shouldn’t be following up.

Keeping track of all of these contacts as more surface and current contacts go cold can be a daunting task if not managed properly. Using client relationship management software can make this process much easier, however, it still requires a diligent effort if you wish to get maximum utility out of all the meetings you have.

Venture Philanthropy: Fast, Disciplined, and Getting People Started

25 Sep

By Shaoyu Chang, Research Analyst, LSN

Shaoyu 10*10Venture philanthropy investment is playing an increasingly important role in early stage life science innovation. More and more, nonprofit foundations are partnering with start-up companies to advance science and address unmet needs. At the recent Redefining Early Stage Investments Conference in Boston, leaders from five prominent foundations gathered for a discussion on the evolving landscape of venture philanthropy in life science research.

At a time when traditional funding sources for life science are on the decline, venture philanthropists are stepping in to fill some of the gaps. “We are looking at the emerging markets of tomorrow. They might not be big, but they are not inexistent” said a program investment officer with a leading foundation in global health. “We are trying hard to find the right mix of commercially viable companies that can serve our charitable goals.”

Unlike traditional grant-making foundations, to facilitate innovations, venture philanthropy investors offer science expertise and business management skills in addition to their investment dollars. “Money is not enough. It is essential that you are part of the process,” said the founder of a nonprofit fund dedicated to the treatment of rare diseases. The resources of this fund helped establish a biotech start-up that is advancing new therapies through clinical trials.

The risk involved in early-stage life science innovation makes it difficult to raise funds from increasingly risk-averse venture capital investors. By contrast, venture philanthropy investors are more willing to accept these risks. “Our goal is to de-risk early-stage research,” said the CEO of a foundation that focuses on autoimmune diseases. “Our measure of success is not the number of new therapies approved, but that new therapies are tested more frequently and quickly.”

To achieve the dual goals of social impact and business success, venture philanthropy investors are now expecting specific outcomes from their strategic partnerships. In addition to milestones in scientific development, many foundations are now sitting on management boards and are receiving returns on investment upon commercialization of the research that they have funded. The view on nonprofits as non-dilutive capital is outdated.

Besides funding, venture philanthropy can bring much more to the table, from access to top-tier research institutions to patient group connections. “We are fast, disciplined, and can get people started,” said the CEO of a fund devoted to neurodegerative diseases.

As venture philanthropy grows in significance for early stage investment, start-ups will find opportunities for new strategic partnerships. Scientist-entrepreneurs should feel encouraged to reach out to philanthropic funds, showcase the strength of their science, and demonstrate how their big ideas can align both commercial potential and philanthropic mission.

Hot Life Science Investor Mandate 1: Corporate Venture Capital Seeking Early Stage Therapeutics in for a Wide Range of Indications

25 Sep

The Corporate Venture Capital Arm of large pharma company is currently investing from its second fund of $100M. The firm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to the firm’s parent company. The firm typically invests (equity) $3-$4M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. The firm seeks to make about 2-3 allocations in the next 6-9 months.

The firm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase IIa. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics and Healthcare IT

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Virtual Pharma Company Seeking to In-License Early Stage Therapeutic Assets

25 Sep

An innovative global private equity firm utilizing a virtual pharma (asset centric) model is looking to invest in early stage pharmaceutical assets, and is capable of providing $15-$20 million or more to get a project through proof of concept. The firm prefers to acquire or in-license individual pharmaceutical assets and is much less likely to make traditional equity investments into companies. Ideal candidates have yet to receive significant VC funding and the firm prefers to invest without syndicates. The firm in interested in investing in projects around the globe and is capable of making 15+ investments over the course of the next year if enough high quality investments present themselves.

The firm is looking primarily for pharmaceutical assets and to a much lesser extent diagnostics and medical devices. The firm is willing to invest in assets that are as far as 12-18 months pre-IND to those that are early in phase I of clinical trials and ideal candidates are IND ready and preparing to enter phase I. The firm is open to all indications where proof of concept can be shown in early clinical trials which generally excludes assets targeting a number of CNS disorders. For medical device and diagnostic opportunities only very select programs of extreme appeal will be considered.

The firm is looking to partner with management teams that have an extreme understanding of the science behind their product and that are willing to operate in a virtual environment. The firm acts as an extremely hands on investor often integrating investments into the parent company and ensuring that all assets are developed in the most effective and risk-diversified manner.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: PE Fund Seeking Later Stage Therapeutics, Devices and Diagnostics

25 Sep

A Private Equity group based in the Eastern United States is looking for new firms for potential investments for the firm’s third fund and could make as many as 10 investment over the next year. The firm looks to make equity investments into companies looking to raise a total round of $20-$50 million generally set up in tranches. The firm looks to invest in companies across the United States and Europe with a focus on companies located in the United States.

The firm is interested in Therapeutics, Medical Devices and Diagnostics, though the majority of the firm’s investments have been into the therapeutics space. The firm is primarily interested in later stage opportunities, with a focus on therapeutics that are in Phase II or later and devices and diagnostics that are well into their clinical trial or are already on the market. The firm is opportunistic across technologies types and indications although historically they have worked with a number of companies in the oncology and infectious disease spaces.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both public and privately held companies with a preference for those that are private. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

RESI Innovation Challenge: Who Knocked it Out of the Park at the Home of the Boston Red Sox?

18 Sep

By Nono Hu, Senior Manager, Branding & Messaging, LSN

Nono 2

At LSN’s third Redefining Early Stage Investments (RESI) Conference, 32 pre-screened medtech and biotech companies competed to be crowned the winner of the RESI Innovation Challenge. All attendees were given RESI Cash with which they could “Invest” in their favorite presenting company at the show and whoever was able to raise the most RESI Cash as deemed the winner.

Scroll down to see the winning companies below (click the logos to visit company websites):

FIRST PLACE:

ORIG3N

ORIG3N, based in Boston, MA, is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology. This will replace the trial & error guess work of treating disease and enable longer, healthier lives.

The company’s executive team is made up of industry veterans with greater than 20 years each in the life sciences marketplace.

ORIG3N Team at RESI 3

ORIG3N Team at RESI 3: Tisha Williams, Representative | Robin Smith, CEO | Kate Blanchard, COO


SECOND PLACE:

SpineThera

SpineThera, based in Minneapolis, MN, develops novel, sustained-release, injectable drugs to treat pain; offering patients and physicians alternatives that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.

SpineThera-Jeff-

Jeff Missling, CEO


THIRD PLACE:

biosortia

Biosortia Pharmaceuticals, based in Dublin, Ohio, has opened the door to a new frontier of fascinating natural products and potential drug candidates by overcoming the challenges of accessing novel high quality bioactive compounds from uncultuable aquatic microorganisms. Biosortia’s business model is to monetize its developing library through a highly profitable licensing model.

Dieck Kurt-Biosortia

Kurt Dieck, President and CEO